Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Although in vitro models have been a cornerstone of anti-cancer drug development, their direct applicability to clinical cancer research has been uncertain. Using a state-of-the-art Taqman-based quantitative RT-PCR assay, we investigated the multidrug resistance (MDR) transcriptome of six cancer types, in established cancer cell lines (grown in monolayer, 3D scaffold, or in xenograft) and clinical samples, either containing >75% tumor cells or microdissected. The MDR transcriptome was determined a priori based on an extensive curation of the literature published during the last three decades, which led to the enumeration of 380 genes. No correlation was found between clinical samples and established cancer cell lines. As expected, we found up-regulation of genes that would facilitate survival across all cultured cancer cell lines evaluated. More troubling, however, were data showing that all of the cell lines, grown either in vitro or in vivo, bear more resemblance to each other, regardless of the tissue of origin, than to the clinical samples they are supposed to model. Although cultured cells can be used to study many aspects of cancer biology and response of cells to drugs, this study emphasizes the necessity for new in vitro cancer models and the use of primary tumor models in which gene expression can be manipulated and small molecules tested in a setting that more closely mimics the in vivo cancer microenvironment so as to avoid radical changes in gene expression profiles brought on by extended periods of cell culture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Established cell cultures have been the predominant research models of osteosarcoma for decades, but the culture-related alterations that cell lines acquire over tens and sometimes hundreds of passages 220,221 led to the development of systems for propagating osteosarcoma tumours 220,221 by creating libraries of primary tumour cell cultures and patient-derived xenografts (PDXs).”
From Osteosarcoma (2022) · cites this paper as [220]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, it has been shown that established cell lines do not capture disease heterogeneity across patients and hence are lacking in clinical relevance (Gillet et al., 2011; Yee et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Gillet et al., 2011
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Our results confirm the low translational relevance of established cancer cell lines for the identification of clinical anti-cancer drug resistance [38].”
From Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients (2022) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 1×
“Among those genes, ATP-binding cassette (ABC) transporters, a superfamily of 48 highly homologous members classified in seven subfamilies, have an important role in the pleiotropic mechanisms mediating MDR by exporting chemotherapeutic agents from the cell (14, 15).”
BackgroundSelf-citationA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
Cytoplasmic functions of the tumour suppressor p53
Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106 · cited 1×
“It is clearly possible that p53 pathway activation results from selective pressure in the tissue culture environment, in turn causing the up-regulation of stress response genes across all cell lines and contributing to the uniformity of the MDR gene expression pattern (35).”
BackgroundO'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
Mechanisms of Multidrug Resistance in Cancer
Gillet, J.-P., & Gottesman, M. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_4 · Cited by 685
Cited by
Items 401–476 of 476
Predictive markers for chemotherapy response in breast cancer.
Steenkamer, M. (2012) · Utrecht University Repository (Utrecht University)
The Role and Regulation of the Phosphatase PPM1D in Chemoresistant Gynecological Cancers
Ali, A. (2014) · uO Research (University of Ottawa) · doi:10.20381/ruor-3512
Introduction: Experimental Metastasis
Malek, A. V. (2013) · Springer eBooks · doi:10.1007/978-94-007-7835-1_1
Miranda, M. A. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2015.tde-25092015-151741
Wright, D. W. (2015) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Acute myeloid leukemia - Apoptotic signalling and gene expression associated with treatment response
Stenke, L., Kanter, L., Gjertsen, B. T., Bergen, U., Lehmann, D. S., Larsson, C., & Smedmyr, B. (2013)
Using genetics to identify epigenetic and signal transduction targets in cancer
Bhadury, J. (2016) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Why Chemotherapy Does Not Work: Cancer Genome Evolution and the Illusion of Oncogene Addiction
Stepanenko, A. A., & Kavsan, V. (2016) · Springer eBooks · doi:10.1007/978-3-319-29716-3_13
An overview on potential of in vitro studies and transcriptomics for cancer
Soni, P., Gupta, S., Laeeq, S., & Bhatt, M. (2017) · Cancer Reports and Reviews · doi:10.15761/crr.1000130
“However a striking observation was found for eight cancer types of the NCI-60panel (A panel of 60 cancer cell line) that all of the cell lines either grown in vitro or in vivo bore more resemblance to each other, regardless of the tissue of origin, than to the clinical samples that they are supposed to model [22,74,75…”
BackgroundWang, Z. C. (2013) · TSpace (University of Toronto)
Regulation of lysophosphatidate-induced mechanisms of chemo-resistance
Venkatraman, G. (2015) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3bn9x79k
The effect mechanism of Ginnalin A as a homeopathic agent on various cancer cell lines
Vural, H. C. (2018) · Open Chemistry · doi:10.1515/chem-2018-0084
“Taking control of this disease and treating it is is extremely difficult and therefore alternatives to medical treatment have been developed [1,2].”
BackgroundCOMPREHENSIVE IN SILICO ASSESSMENT OF CANCER CELL LINE FIDELITY
PavithraKumar, P.-N. (2017)
Fowlkes, N. W. (2018) · Louisiana State University · doi:10.31390/gradschool_dissertations.4669
iMALDI as a tool to improve patient stratification for targeted cancer therapies
Popp, R. (2018) · UVic’s Research and Learning Repository (University of Victoria)
Dean, T. (2018) · TSpace (University of Toronto)
Markwell, S. M. (2018) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.3685
“unidentified site(s) in the NTA region (21), as well as residues near the DDW region in”
BackgroundRecent Progress in Patient-Derived Tumor Xenograft Model of Breast Cancer
Ma, L., Zhan, J., & Zhang, H. (2016) · Scientia Sinica Vitae · doi:10.1360/n052015-00386
Murakami, M. A. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Pal, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-805274-7.00013-0
In Vitro and In Vivo Model Systems of Cholangiocarcinoma
Brandi, G., & Tavolari, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-70936-5_22
Three-dimensional in vitro models to study potentiation of glioblastoma resistance by hypoxia
Musah-Eroje, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00021-x · Cited by 1
Ehmsen, S., Pedersen, M. H., Wang, G., Terp, M. G., Arslanagic, A., Hood, B. L., Conrads, T. P., Leth‐Larsen, R., & Ditzel, H. J. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3281654
Potentiation of Bio Repositories In Personalized Medicine: Tumor Cells Establishment
Li, C. (2017) · Cancer Research and Cellular Therapeutics · doi:10.31579/2640-1053/003
Zhang, H., Ma, J., Wang, J., Moore, W., & Liang, Z. (2017) · Cancer Research and Cellular Therapeutics · doi:10.31579/2640-1053/009
Drapkin, R. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718058147.793481546
Chemoresistance and metastasis in colorectal cancer
Wong, S. Q. R. (2022) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/155418
The Molecular and Biochemical Variations during Cancer Prognosis in Mouse Models
Yodhaanjali, J. R., Dinesan, A., Basalingappa, K. M., & Gopenath, T. S. (2022) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-1282-5_51-1
Comparison of adherent and non-adherent cell phenotypes of breast carcinoma cultures
Shamshurina, E. O., Mogilenskikh, A. S., Grebenyuk, E. V., Samokhina, V. S., Sazonov, S. V., & Демидов, С. М. (2022) · Ural Medical Journal · doi:10.52420/2071-5943-2022-21-6-89-94
(2022) · Biointerface Research in Applied Chemistry · doi:10.33263/briac134.336
Animal Models of Gynecological Cancers
Venkata, P. P., Medina, D., Nirzhor, S. S. R., Sittadjody, S., Kumaran, R., Ramachandran, I., & Subbarayalu, P. (2023) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-3824-5_18
Rottenberg, S., Vollebergh, M. A., de Hoon, B., de Ronde, J., Schouten, P. C., Kersbergen, A. J., Zander, S. A. L., Pajic, M., Jaspers, J. E., Jonkers, M., et al. (2023) · doi:10.1158/0008-5472.c.6503906.v1
Establishment of Humanized Mice And Its Application Progress in Cancer Immunotherapy
Ding, T., Yu, Y., Pan, X., & Chen, H. (2023) · Immunotherapy · doi:10.2217/imt-2022-0148
Wu, M., Liu, Y., Zhao, Y., Zhang, Y., Huang, L., Du, Q., Zhang, T., Zhong, Z., Luo, H., & Xiao, K. (2023) · Journal of Visualized Experiments · doi:10.3791/64623
CONTROLE DE QUALIDADE E SEGURANÇA
da Silva, M. V., & Müller, R. (2023) · doi:10.22533/at.ed.82423100813
Falcone, C., Campbell, D. C. D. P., da Silva, K. S. M., & de Lima, M. R. (2023) · doi:10.22533/at.ed.8242310082
EUTANÁSIA PARA ROEDORES E LAGOMORFOS
Pinto, M. S. F. (2023) · doi:10.22533/at.ed.82423100814
PRODUÇÃO DE ANTICORPOS POLICLONAIS
dos Santos, I. B. (2023) · doi:10.22533/at.ed.8242310088
AVALIAÇÃO E INTERVENÇÃO CLÍNICA EM MODELO MURINO
de Lima, M. R. (2023) · doi:10.22533/at.ed.8242310084
FINALIZAÇÃO HUMANITÁRIA: LEGISLAÇÃO BRASILEIRA E A IMPORTÂNCIA DO ENSINO
Rossi, M. I. D., & Abbagliato, A. S. (2023) · doi:10.22533/at.ed.8242310083
CIRURGIAS EXPERIMENTAIS E PONTO FINAL HUMANITÁRIO EM BIOMODELOS ANIMAIS
Ribeiro, W. L. C., de Almeida, C. A. S., & Oliveira, A. C. A. (2023) · doi:10.22533/at.ed.8242310089
CONCEITOS GERAIS EM CIÊNCIA EM ANIMAIS DE LABORATÓRIO E FINALIZAÇÃO HUMANITÁRIA
Campbell, D. C. D. P. (2023) · doi:10.22533/at.ed.8242310081
da Silva, J. D. P. A., de Lima, M. R., & Campbell, D. C. D. P. (2023) · doi:10.22533/at.ed.82423100812
In vitro study of efficacy of pramlintide in osteosarcoma
Sangsin, A. (2016) · Chula Digiverse · doi:10.58837/chula.the.2016.1323
Evolution of Genes and Transcripts Modifies Drug Sensitivity in Cancer Cell Lines - A Review
Sahu, K., & Jain, U. (2023) · Journal of Angiotherapy · doi:10.25163/angiotherapy.729397
Bio-markers of immuno-oncology
Patel, T. D., Gunjan, & Vanteddu, V. G. (2024) · Journal of Pharmaceutical and Biological Sciences · doi:10.18231/j.jpbs.2023.017
Topolnitska, D., Moreno, C. L., Paiva, A., Buchel, E. W., Safneck, J. R., & Raouf, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.09.598157
Miyazaki, K., Hoshino, D., Kasajima, R., Koizume, S., Koshikawa, N., & Miyagi, Y. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114188
Application of Deep Learning Methods in Prediction of Anticancer Drug Susceptibility
张, 金. (2024) · Artificial Intelligence and Robotics Research · doi:10.12677/airr.2024.133062
Kanser Kök Hücre Proliferasyonunun Akciğer Kanseri Hastalarında Pilot Bir Çalışma ile Belirlenmesi
Yılmaz, S., Sarıkaya, M. D., Bağcı, B. Ş., Beşparmak, E. A., Yaşar, E., Önal, Ö., & Canöz, Ö. (2024) · Bozok Tıp Dergisi · doi:10.16919/bozoktip.1504469
Lee, U., Szabova, L., Collins, V. J., Gordon, M. B., Johnson, K., Householder, D. B., Jorgensen, S., Lu, L., Bassel, L., Elloumi, F., et al. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1462840 · Cited by 1
Miranda, M. A., Sares, C., Andrade, A. F., Borges, K. S., McChesney, J. D., Bastos, J. K., & dos Reis, R. B. (2023) · Armaghan. · doi:10.61186/jmp.22.88.1
Patient-Derived Three-Dimensional Lung Tumor Models to Evaluate Response to ImmunotherapyPreprint
Goliwas, K. F., Hough, K. P., Sivan, S., Single, S. L., Deshmukh, S. S., Berry, J. L., Khalil, M., Wei, B., Boumber, Y., Athar, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.19.654890
Establishment and characterization of preclinical model of primary ovarian squamous cell carcinoma
Xu, C., Xu, W., Wu, C., Chen, X., Ma, Z., Wang, J., Zhuo, Y., Cai, X., Zhang, Y., Lyu, Y., et al. (2025) · Human Cell · doi:10.1007/s13577-025-01253-4
Jiang, A. Y. L., Yale, A. R., Hanamoto, J. N., Lav, N. S., Dang, V., Ro, C. C., Douglas, C., Di, K., Deyell, J., Bota, D. A., et al. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70069 · Cited by 1
“25 Thus, there is a need for alternative strategies to rapidly enrich TMZ-resistant cells and bypass extended culture in TMZ.”
Meaney, C., Mohammadrezaei, D., & Kohandel, M. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780192867636.003.0032
Stancu, G. (2025) · Cureus · doi:10.7759/cureus.94367
“This starkly contrasts with the rapid senescence observed in Patients 1-4, underscoring the significant inter-patient heterogeneity inherent in primary cancer cell culture [16].”
Oxazole Analogues as Potential Therapeutic Agents: A Comprehensive Review
Goel, N., Mudgil, S., Kasnia, R., Demiwal, S., & Nehra, B. (2025) · Pharmaceutical Fronts · doi:10.1055/a-2728-8329 · Cited by 1
Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates
Weinfurtner, K. M., Amin, R., Skuli, N., Gade, T. P. F., & Kaplan, D. E. (2026) · Seminars in Liver Disease · doi:10.1055/a-2779-4984
Systematic Evaluation of Transfer Learning Strategies for Clinical Chemotherapy Response PredictionPreprint
Du, H., & Ballester, P. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.16.706121
“…demonstrate strong predictive performance in vitro, the translational value of cell-line-trained models is debated since cell lines differ from patient tumours in critical ways, including the absence of tumour microenvironment, altered baseline gene expression, and reduced heterogeneity 23 , 24 .”
Berényi, E. (2026) · Biochemistry · doi:10.5772/intechopen.1011997 · Cited by 1
Mansouri, A., Hart, O., Aslanabadi, S., Hartupee, C. D., Yalcin, D., Sinha, G., Chabu, C. Y., Cios, A., Cheng, Z., Ammanamanchi, S., et al. (2026) · Cells · doi:10.3390/cells15060531
“Conversely, tumor-cell monoculture systems sacrifice microenvironmental complexity but provide high-resolution insight into tumor-intrinsic molecular mechanisms [65,66].”
In-Depth Characterization of Human Retinoblastoma Subtype 2 and Preclinical Models
Ottaviani, D. (2019) · theses.fr (ABES) · doi:10.70675/3cd1c4dczbe7cz4810zbb60z4ff8351857ce
Role of glial cells during rabies virus infection
Feige, L. (2021) · theses.fr (ABES) · doi:10.70675/c423b214z3cc0z4976za6fazc5bc61c40274
Drug Sensitivity and Clonal Evolution Under Targeted Treatment of High-Risk Neuroblastoma
Jiménez, I. (2021) · theses.fr (ABES) · doi:10.70675/1d5309abz141dz465cz8315z7f533fec6e34
Targeting the cell cycle : A novel therapeutic strategy against ATIP3- deficient breast cancer
Haykal, M. M. (2023) · theses.fr (ABES) · doi:10.70675/03dee32bz395cz469ez9a0dzf4c5f2e84330
de Man, S. M. A., Aksoy, E. K., Veenendaal, T., Meesters, N., Chavez-Abiega, S., Yan, X., Kop, M., Gandini, L., Flach, J., Meng, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1721016
Qin, X., Zhao, Y., Wu, Y., Efelis, A., Paul, R., Islam, K., Marquez, C. S., Liu, Y., & Liu, Y. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c01908
Si, W., Zhou, J., & Jiang, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1864153 · Cited by 1
Zhou, F., Wang, C., Mo, L., Sun, X., & Zhang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1859926 · Cited by 1
Data-centric feedback loops for next-generation immunotherapy development
Shalita, R., & Amit, I. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01785-6
Gadelkarim, M., Elsayed, A., Abaza, T., Bahr, A. R., Elsayed, Y. A.-E., & Iqbal, O. (2026) · Clinical Cancer Bulletin · doi:10.1007/s44272-026-00067-1
“Evidence supports their utility in investigating metastasis [2], drug sensitivity [3] or resistance [4], and cell signaling [5].”
Beyond the flask: cancer cell lines and the limits of biological extrapolation
Bekheir, S. A., Maghsoudi, A. S., Alizadeh, A. M., & Abdollahi, M. R. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101470
Microarray-Based Investigations in Cancer
Starmans, M. H. W., Haider, S. A., Yao, C. Q., Lambin, P., & Boutros, P. C. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8050-2_7
Metadata
- Authors
- Gillet, J.-P., Calcagno, A. M., Varma, S., Marino, M., Green, L. J., Vora, M. I., Patel, C., Orina, J. N., Eliseeva, T. A., Singal, V., Padmanabhan, R., Davidson, B., Ganapathi, R., Sood, A. K., Rueda, B. R., Ambudkar, S. V., & Gottesman, M. M.
- Affiliations
- National Cancer Institute (UA)
- National Institutes of Health (US)
- Biophase Systems, Fremont, CA 94539;
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2011-11-08
- Volume
- 108
- Issue
- 46
- Pages
- 18708-18713
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3219108
- OpenAlex
- W2018044006
- Cited by
- 477
- References
- 46
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 25 · 2023: 43 · 2022: 28 · 2021: 34 · 2020: 41 · 2019: 45 · 2018: 33 · 2017: 46 · 2016: 40 · 2015: 40 · 2014: 20 · 2013: 29 · 2012: 16
- FWCI
- 10.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Repository of the University of Namur (submittedVersion)
- Funders
- Georgetown University
- Karolinska Institutet
- National Institutes of Health
- Lombardi Comprehensive Cancer Center, Georgetown University
- National Cancer Institute (NCI-60)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- cancer cell lines, multidrug resistance, drug resistance mechanisms, xenografts, 3D cell culture, gene expression profiles, in vitro tumor model, tumor microenvironment
- MeSH terms
- Antineoplastic Agents, Cell Survival, Drug Screening Assays, Antitumor, Female, Humans, Ovarian Neoplasms, Ovary, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Cell Line, Tumor, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.